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A rare immunohistochemical study using 28 surgical sections of human chondrosarcoma revealed that 67.9% of tumour cells had
weak (10-40%) or strong (440%) positive immunoreaction for peroxisome proliferator-activated receptor-g. The expression of
peroxisome proliferator-activated receptor-g mRNA and protein in human chondrosarcoma cell line OUMS-27 was also
determined by reverse transcription-polymerase chain reaction and immunocytochemistry, respectively. Furthermore, the effects
of peroxisome proliferator-activated receptor-g ligands on cell proliferation and survival were investigated in OUMS-27 cells.
Pioglitazone, a selective ligand for peroxisome proliferator-activated receptor-g, and 15-deoxy-D
12,14-prostaglandin J2 (15d-
PGJ2), a putative endogenous ligand for peroxisome proliferator-activated receptor-g, inhibited the proliferation of OUMS-27
cells in a dose-dependent manner. The mechanism of cytotoxic effects of 15d-PGJ2 was via apoptosis as shown by DNA
fragmentation using TUNEL stain and DNA ladder formation, and by ultrastructural analysis using transmission electron
microscopy. Flow-cytometric analysis using annexin-V-ﬂuorescein and propidium iodide detected the early change of apoptosis,
as well as necrosis of OUMS-27 cells at 4 h after co-incubation with 15d-PGJ2. These results suggest that peroxisome
proliferator-activated receptor-g may play a signiﬁcant role in the pathogenesis of chondrosarcoma, and peroxisome proliferator-
activated receptor-g ligands, especially 15d-PGJ2, may be of therapeutic value in the treatment of human chondrosarcoma.
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Peroxisome proliferator-activated receptors (PPARs) are members
of the nuclear receptor superfamily of ligand-activated transcrip-
tion factors. To date, three mammalian PPAR subtypes have
been isolated, and termed PPARa, PPARd and PPARg, which
heterodimerise with the retinoid X receptors (Kliewer et al,
1992). PPARa is predominantly expressed in the liver, and studies
have focused on its role in lipid metabolism (Latruffe and Vamecq,
2000). PPARd is ubiquitously expressed, but its function is not well
understood. Although PPARg was ﬁrst found to be expressed at
high levels in adipose tissue, and functions as a critical regulator
of adipocyte differentiation and fat metabolism (Chawla et al,
1994), the expression of PPARg is not restricted to the cells of
the adipocytic lineage, and has been demonstrated in many other
human cell types including chondrocytes (Bordji et al, 2000).
Induction of differentiation and apoptosis in cancer cells by
ligands of PPARg is a novel therapeutic approach against malignant
tumours. Recent studies reported that 15-deoxy-D
12,14-prostaglandin
J2 (15d-PGJ2), the most potent endogenous ligand for PPARg, and
the synthetic PPARg ligand thiazolidinedione (TZD) can induce
terminal differentiation and growth inhibition of human liposarcoma
(Tontonoz et al, 1997), breast (Elstner et al, 1998; Yee et al, 1999),
prostate (Kubota et al, 1998), colon (Sarraf et al, 1998; Kitamura et
al, 1999), gastric (Takahashi et al, 1999; Sato et al, 2000), lung (Chang
and Szabo, 2000; Tsubouchi et al, 2000), and pancreas (Motomura et
al, 2000; Elnemr et al, 2000) cancer cells, as well as hepatoma cells
(Koga et al, 2001) in vitro and in vivo. The in vivo induction of histo-
logical and biochemical differentiation of liposarcomas by clinical
trial of troglitazone administration was reported by Demetri et al
(1999). Among these patients the immunohistochemical expression
of Ki-67, a marker of cell proliferation was markedly reduced. The
authors of a similar in vivo trial have suggested the clinical efﬁcacy
of troglitazone in prostate cancer (Mueller et al, 2000). Although
the precise mechanism is still unknown, the interference in tumour
cell growth by PPARg ligands may have a favourable clinical effect.
Chondrosarcoma is a relatively rare malignant bone tumour
accounting for only 3–6% of primary bone tumours (Mirra, 1989;
Schajowics, 1994; Unni, 1996). The histologic grade of chondrosar-
coma which indicates the differentiation status of tumour cells, is
one of the most important factors for the prognosis of the disease
(Evans et al, 1977). The surgical treatment of chondrosarcoma with
adequate marginal resection is effective for low-grade chondrosarco-
ma with better clinical outcomes (Ozaki et al, 1996). However, for
high-grade chondrosarcoma, the prognosis is poor even after
adequate surgery (Sheth et al, 1996), the efﬁcacy of systemic
chemotherapy or irradiation is still unclear. Thus, the development
of clinically useful agents which inhibit cell growth and induce cell
death may be useful in the treatment of chondrosarcoma.
In the current study, the ﬁrst of its kind, the authors examined
the expression of PPARg both in surgically resected sections of
human chondrosarcoma and OUMS-27 cells (Kunisada et al,
1998), a novel cell line established from a grade III human chon-
drosarcoma of a 65-year-old male. The examination of the effects
of PPARg ligands on OUMS-27 cells demonstrated that PPARg
ligands inhibited cell proliferation in a dose-dependent manner,
and induced apoptosis of OUMS-27. The ﬁndings of the current
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MATERIALS AND METHODS
Immunohistochemistry on patient specimens and
semiquantitative analysis
Immunohistochemistry was performed as previously described
(Nishida et al, 2001) on formalin-ﬁxed, parafﬁn-embedded tissues
of human chondrosarcoma surgically resected from 28 patients.
Brieﬂy, sections were treated by polyclonal anti-human PPARg
antibody (Afﬁnity BioReagents, Inc, Golden, CO, USA) diluted
into 10 mgm l
71 with PBS containing 0.1% NaN3 and 0.1% bovine
serum albumin (British Biocell International Co, UK). After incu-
bation for 30 min at room temperature with 7.5 mgm l
71 of
biotinylated goat anti-rabbit IgG (Vector Laboratories Inc, CA,
USA), tissues were then treated by ABC method for 30 min, visua-
lised with diaminobenzidine (DAB) (Sigma) in H2O2 (0.01%) for
5 min, and counterstained with methyl-green. Negative control
was obtained in the same fashion but excluding the primary anti-
body. They were then examined under a light microscope.
Each specimen showed pathologically different grades of chon-
drosarcoma; grade I (n=20), grade II (n=6) and grade III (n=2).
For the semiquantitative analysis of PPARg positive tumour cells
in the human tissue, the amount of the staining was evaluated in
each of the three grades of chondrosarcoma.
Cells and cell culture
The human chondrosarcoma cell line OUMS-27 was a generous
gift from Dr Masayosi Namba (Okayama University Medical
School, Japan). OUMS-27 is a cell line established from grade III
chondrosarcoma of a 65-year-old patient. The cells were cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
450 mg dl
71 glucose, supplemented with 10% foetal bovine serum
(FBS) (Life Technologies, Rockville, MD, USA), 100 U ml
71 peni-
cillin, and 100 mgm l
71 streptomycin (Life Technologies). Cells
were incubated at 378C in a humidiﬁed atmosphere of 5% CO2
in air. Cells were sub-cultured at a split ratio of 1:3 every 7–10
days with 0.1% trypsin (Life Technologies), 5 mM EDTA solution.
The medium was regularly changed twice a week.
RNA extraction and RT–PCR
Total cellular RNA was extracted from conﬂuent cells using the RNA
plus kit (Bioprobe System, Montreuil, France). For reverse transcrip-
tase-polymerase chain reaction (RT–PCR), RNA samples (5 mg)
were reverse-transcribed to cDNA using reverse transcriptase (Rever-
Tra Ace, Toyobo Co. Ltd., Osaka, Japan) and subsequently ampliﬁed
by PCR using as a sense primer, 5'-TCTCTCCGTAATGGAAGACC-
3' and an antisense primer, 5'-GCATTATGAGAC-ATCCCCAC-3' as
previously reported (Takahashi et al, 1999). Human adult normal
adipose total RNA was purchased from BioChain Institute, Inc, CA,
USA (Catalogue Number 061005). Samples were reverse-transcribed
to cDNA and used for the positive control of PPARg mRNA expres-
sion. The reaction conditions were as follows: initial denaturation at
948C for 2 min and 30 cycles of ampliﬁcation (30 s at 948C, 30 s at
588C,and40 sat728C)inanautomatedthermal cycler(Perkin Elmer
Applied Biosystems, Foster, CA, USA), followed by a ﬁnal extension
step of 4 min at 728C. PCR products were run on 1% agarose gels.
Immunocytochemistry
The expression of PPARg at the protein level was determined by
immunocytochemistry. Brieﬂy, cells were cultured at a density of
1610
5 cells per well in 6-well plastic culture dishes (Primaria,
France), and ﬁxed in 2% paraformaldehyde in 0.1 M phosphate
buffered saline (PBS, pH 7.4) for 30 min at room temperature,
washed in PBS. After permeabilisation in 0.1% Triton X-100 (Naca-
lai Tesque Inc., Kyoto, Japan) for 5 min at room temperature, non-
speciﬁc staining was blocked by 10% normal goat serum (Vector
Laboratories, Burlingame, CA, USA). Immunocytochemistry for
PPARg was performed in the same fashion as described above.
Reagents for activation of PPARg
Pioglitazone, a selective ligand for PPARg, was kindly provided
from Takeda Chemical Industries (Osaka, Japan). 15d-PGJ2,a
potent natural ligand for PPARg, was purchased (from Biomol
Research Laboratories, Inc, MI, USA). These PPARg ligands were
dissolved in dimethyl sulphoxide (DMSO) with a ﬁnal concentra-
tion of 0.1% DMSO in the culture medium.
Cell proliferation and viability assay
Cells were seeded at 1610
4 cells per well in a 96-well culture plate
or 8-well culture plate (Coster, Cambridge, MA, USA) in 100 ml
10% FCS-DMEM and incubated for 24 h at 278C. For the activa-
tion of PPARg, cells were treated with increasing concentrations of
pioglitazone and 15d-PGJ2 for 24 h.
To know the effects of pioglitazone and 15d-PGJ2 on the prolif-
eration grade of cell growth, an immunocytochemical study was
performed in the same manner as described above on the cells
cultured in 8-well culture plate, using monoclonal anti-Ki-67 anti-
body (Zymed Laboratories Inc, CA, USA) as a primary antibody
and anti-mouse IgG (Vector Laboratories Inc, CA, USA) diluted
to a ﬁnal concentration of 10 mgm l
71 as a secondary antibody.
PBS without primary antibody was used as the negative control.
Semi-quantitative analysis on the Ki-67-immunostained cells were
performed by counting the positive cell number per total cells in
four ﬁelds at a magniﬁcation of 6200 under light microscopy.
Cell viability in a 96-well culture plate was evaluated using the
colorimetric MTT assay (Chemicon International, Inc, Temecula,
CA, USA) according to the manufacturer’s instructions. Quantita-
tion was then conducted using Model 550 microplate reader
(BioRad, Hercules, CA, USA) at 595-655 nm. Results of optimal
density units per 1610
4 adherent cells were expressed as % MTT.
DNA fragmentation analysis
Cells were cultured for 24 h in the presence or absence of 15d-PGJ2
(10 mgm l
71) at a density of 1610
5 cells per well in 6-well plastic
culture dishes. Cells were ﬁxed in 2% paraformaldehyde in PBS
(30 min at room temperature). Cells were then doubly stained by
nick end-labelling method to detect the fragmented DNA, and
Hoechst 33258 (Wako, Osaka, Japan) to observe the nuclear
morphology of the cells. Brieﬂy, cells were ﬁrst incubated with
TdT reaction solution (2 mg terminal deoxynucleotidyle transferase
(TdT) and 5 mg FITC-conjugated deoxyuridine triphosphate (dUTP)
in 1200 ml TdT buffer). The cells were then stained by Hoechst 33258
(10 mgm l
71) for 5 min at room temperature. After thorough wash-
ing in PBS, cells were observed by ﬂuorescent microscopy.
The Apoptotic DNA Ladder Kit (Roche Diagnostics GmbH,
Mannheim, Germany) was used for DNA ladder assay according
to the manufacturer’s instructions. Brieﬂy, cells were cultured in
serum-free DMEM at a density of 2.5610
6 cells in 75 mm
2 tissue
culture ﬂask (Greiner, Frickenhawen, Germany), stimulated with
15d-PGJ2 (10 mgm l
71) for 24 h. Cells were homogenised in lysis
buffer, and DNA was isolated. The samples were separated on a
2% agarose gel and stained with 10 mgm l
71 ethidium bromide.
FACS analysis using annexin-V-FITC
The expression of phosphatidylserine on the outer leaﬂet of apop-
totic cell membranes was examined by ﬂuorescence-activated cell
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nostics GmbH, Mannheim, Germany) was used according to the
manufacturer’s instructions to stain the apoptotic cells and to
differentiate them from necrotic cells. Brieﬂy, cells were seeded at
a density of 1610
6 cells on 25 cm
2 tissue culture ﬂask (Becton
Dickinson, Planklin Lakes, NJ, USA) in serum-free DMEM were
pretreated with 15d-PGJ2 (10 mgm l
71) for 4, 8 and 24 h, washed
with PBS and centrifuged at 200 g for 5 min. Cell pellets were then
re-suspended in 100 ml of 2% Annexin-V-ﬂuorescein labelling
reagent in Hepes buffer containing 2% propidium iodide (PI)
and incubated for 15 min at 15 to 258C. After washing extensively,
stained cells were analysed using a FACScan (Becton Dickinson,
San Jose, CA, USA) and 1000 events in the live gate were recorded
(a 515 nm bandpass ﬁlter for ﬂuorescein and a ﬁlter 4600 nm for
PI detection).
Transmission electron microscopy
Ultrastructural appearances of apoptotic cells were conﬁrmed by
electron microscopic study. Cells were ﬁrst incubated with or with-
out 15d-PGJ2 (10 mgm l
71) for 8 h. Then cells were scraped,
pelletised, rinsed with PBS, and then ﬁxed in 1% glutaraldehyde
in PBS (pH 7.4) overnight at 48C. After rinsing in PBS three times,
cell pellets were dehydrated by a graded series of ethanol, and ﬁnal-
ly embedded in hydrophilic resin (LR-White). Semi-thin sections
were ﬁrst stained by toluidine blue and examined by light micro-
scopy. Adjacent ultra-thin sections were then contrasted with
aquenous uranyle acetate and lead citrate, and examined by a
transmission electron microscope (TEM) (type 7100, Hitachi,
Tokyo).
Statistical analysis
The results are expressed as mean+s.e.m. Statistical analysis was
performed by one way analysis of variance and subsequent Fisher’s
LSD test. P50.05 was considered statistically signiﬁcant.
RESULTS
Expression of PPARg in human chondrosarcoma and
OUMS-27 cells
Immunohistochemical examination revealed that human chondro-
sarcoma cells frequently express PPARg at protein level (Figure 1).
In the nuclei of differentiated chondrocytes showed strong positive
reaction for PPARg, but not in the well differentiated hypertrophic
chondrocytes nor undifferentiated mesenchymal cells. The results
of the semiquantitative analysis for PPARg-positive cells were
summarised in Table 1. The positivity (the cutoff positivity of
10%) of chondrosarcoma cells were 65.0% in grade I, 83.3% in
grade II, and 50.0% in grade III, and overall positivity was
67.9%. RT–PCR analysis was done to examine the expression of
PPARg mRNA in OUMS-27 cells. The predicted band size
(474 bp) of PPARg mRNA was clearly detected in OUMS-27 cells
(Figure 2A). Immunocytochemistry using polyclonal anti-human
PPARg antibody showed the nuclear localisation of PPARg in
OUMS-27 cells. Negative controls treated with non-immune serum
or without primary antibodies showed no positive reaction (Figure
2B a,b). These data indicated that PPARg is frequently expressed
both in primary chondrosarcomas as well as cancer cell line
OUMS-27.
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Figure 1 Expression of PPARg protein of the cells in grade I (A,B) and
grade II (C,D) areas within chondrosarcoma specimens from patients.
Note there are few positive immuno-reactions in the cells in the grade III
areas (E,F). Magniﬁcation; A,C,E 506, B,D,F 1006.
Table 1 Summary of immunohistochemical study for PPARg in human
chondrosarcoma tissues
Pathological grade of chondrosarcoma
I( n=20) II (n=6) III (n=2)
None 7 1 1
Weak 8 2 1
Strong 5 3 0
Positive cell ratios labelled by polyclonal antibodies for PPARg were expressed:
None; 510%, Weak; 10–40%, Strong; 440% of cells positive.
M OUMS-27 AT
A
B
PPARg
Figure 2 Expression of PPARg in OUMS-27 cells. (A) Reverse transcrip-
tion of total RNA into cDNA and RT–PCR was performed using speciﬁc
primers for PPARg. PPARg was expressed at the mRNA level (474 bp) in
OUMS-27 cells (arrow) as well as human adult normal adipose tissue. M:
molecular control, AT: adipose tissue. (B) Immunocytochemical analysis
of PPARg in OUMS-27 cells was performed using polyclonal anti-PPARg
antibodies. a: Nuclear localisation of PPARg protein (arrow heads), b: nega-
tive control.
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After the treatment with two different kinds of PPARg ligands, the
morphologic features of OUMS-27 cells were observed under phase
contrast microscopy. Cells treated with vehicle only (0.1% DMSO)
had a polygonal shape and adhered to the plastic surface. Cells
treated with 15d-PGJ2 at 1 mgm l
71 appeared less active, but still
had a polygonal appearance. When cells were treated with doses
of 15d-PGJ2 at 5 mgm l
71 or higher, they showed relatively round
shapes with cell shrinkage and apoptotic body-like structure and
some cells could no longer adhere to the dish. The treatment with
pioglitazone did not induce so much morphological change when
compared with 15d-PGJ2 treatment (Figure 3A). The results of
immunostain for Ki-67 and MTT assay indicated that both piogli-
tazone and 15d-PGJ2 for 24 h inhibited the cell growth and
reduced cell viability in a dose-dependent manner (Figure 3B,C).
Interestingly, cell growth was markedly reduced when treated with
15d-PGJ2.
Induction of apoptosis of OUMS-27 cells by PPARg ligands
In order to conﬁrm the apoptosis induced by PPARg activation,
DNA fragmentation was analysed both biochemically and morpho-
logically. Hoechst staining showed condensed DNA chromatin
morphology in OUMS-27 cells treated by 15d-PGJ2 for 24 h. The
appearance of these cells was consistent with that of the cells posi-
tive for TUNEL staining which indicate DNA fragmentation
(Figure 4A). Treatment of OUMS-27 cells with 15d-PGJ2
(10 mgm l
71) for 24 h induced DNA ladder formation (Figure
4B). Semi-thin sections of LR-White embedded cells stained by
toluidine blue showed a large number of OUMS-27 cells treated
with 15d-PGJ2 with characteristic apoptotic features; cell shrinkage
and nuclear condensation (Figure 5A,B). TEM study revealed that
untreated OUMS-27 cells have extensive rough-surfaced endoplas-
mic reticulum, thickened mitochondria and numerous cytoplasmic
vesicles (Figure 5C). In contrast, when treated with 15d-PGJ2, the
sections contained many apoptotic cells with condensed chromatin,
many vacuoles in the cytoplasm and membrane budding (Figure
5D). FACS analysis indicated the population of apoptotic cells with
PS at the outer membrane of the cells (annexin-V positive, PI
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
A
015 1 0 2 0 ( µg/ml)
Pioglitazone
15d-PGJ2
015 1 0 2 0 3 0 ( µg/ml)
15d-PGJ2
Pioglitazone
100
80
60
40
20
0
MTT value
(% control)
80
60
40
20
0
(% Ki-67 positive)
B
C
Figure 3 Effect of PPARg ligands on OUMS-27 cell morphology and
proliferation. OUMS-27 cells were cultured and treated with various con-
centrations of pioglitazone, 15d-PGJ2 or vehicle (0.1% DMS) for 24 h. (A)
Under the phase contrast microscopy, cells showed relatively round shapes
with loss of cell volume and detached from the dishes when treated with
doses of 15d-PGJ2 5 mgm l
71 or higher. High dose 15d-PGJ2 treatment
(over 10 mgm l
71) caused cell detachment only 2 h after co-incubation.
Pioglitazone treatment induced fewer morphological changes. (B) To iden-
tify the proliferative grade of cell growth, Ki-67-positive cell index was de-
termined by counting the positive cells per total cells in four ﬁelds. Data are
expressed as mean+s.e.m. of four ﬁelds. *P50.01, when compared with
vehicle only (ligands dose 0 mgm l
71). (C) Cell viability was determined
by MTT assay. Although both PPARg ligands inhibited cell growth in a dose
dependent manner, the effects were more remarkable in 15d-PGJ2.
Hoechst
33258
TUNEL
Control 15d-PGJ2 M AB
Figure 4 Induction of apoptosis by 15d-PGJ2 in OUMS-27. (A) OUMS-27 cells were incubated with or without 15d-PGJ2 (10 mgm l
71) for 24 h. Cells
were doubly stained by Hoechst 33258 and simultaneously analysed by TUNEL stain, and observed by ﬂuorescent microscopy. The cells with morpholo-
gically condensed nucleus were TUNEL positive, indicating the existence of fragmented DNA. (B) DNA was isolated TUNEL positive, indicating the ex-
istence of fragmented DNA. (B) DNA was isolated from the cells after co-incubation with 15d-PGJ2 (10 mgm l
71) for 24 h. A clear DNA-ladder formation
was obtained after electrophoresis on a 2% agarose gel. M: marker.
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necrotic cells (annexin-V positive, PI positive) were approximately
22.3 and 21.4% at 4 and 24 h, respectively, after treatment with
15d-PGJ2 (Figure 6).
DISCUSSION
There are few human chondrosarcoma cell lines with chondrocytic
properties, OUMS-27 is a novel cell line established from grade III
human chondrosarcoma by Kunisada et al (1998). OUMS-27 cells
do not show contact inhibition after reaching conﬂuence and grow
rapidly in multiple layers. The cells express proteoglycan, as well as
type I, II, III, IX and XI collagen after 120 passages, showing stable
maintenance of the differentiated chondroctic properties. The
transplantation of OUMS-27 cells into athymic mice resulted in
formation of grade II (of III) chondrosarcoma at injected site
(Kunisada et al, 1998). Thus, the OUMS-27 cell line appears to
be a useful model for studies for chondrocyte function as well as
the aetiology and treatment of human chondrosarcoma.
Recent studies strongly suggest the attractive concept that
PPARg ligands might be useful agents in the induction of cell
differentiation or apoptosis in cancer cells. In the current study,
the authors demonstrated for the ﬁrst time that PPARg is expressed
in both surgically resected human chondrosarcoma and OUMS-27
cells. The frequent expression of PPARg in chondrosarcoma cells
indicated the involvement of PPARg in the pathogenesis of chon-
drosarcoma and suggested the possible inhibitory effect on cancer
cell growth and proliferation by PPARg activation.
TUNEL staining, DNA ladder formation and TEM revealed that
the type of cell death induced by 15d-PGJ2 was apoptosis. Interest-
ingly, early apoptotic change, and the translocation of
phosphatidylserine on the outer leaﬂet of the cell membrane were
demonstrated only 4 h after co-incubation with 15d-PGJ2. To date,
the exact intracellular signaling pathways leading to apoptotic cell
death following speciﬁc activation of PPARg is not fully under-
stood, several factors have been suggested to be involved in
PPARg ligand-induced apoptosis. The activation and actin of
caspases is believed to be a pivotal step in the mechanism of apop-
tosis. In JEG3 choriocarcinoma cells, 15d-PGJ2-induced apoptosis
measured by a decline in MTT activity was signiﬁcantly inhibited
by the caspase inhibitor ZVAD-fmk, but the inhibitory effect was
up to 50% (Keelan et al, 1999). Previous reports suggested the
involvement of a caspase-3-independent mechanism in 15d-PGJ2-
induced loss of MTT activity (Miyashita et al, 1998). We found
that the inhibitors for caspase-1, 3, 8, 9, and ZVAD-fmk (2 mM)
did not have signiﬁcant effect on the 15d-PGJ2-induced loss of
MTT activity in OUMS-27 (data not shown). It is speculated that
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Figure 5 Cell morphology after incubation with or without 15d-PGJ2.
The cells were treated by 10 mgm l
72 of 15d-PGJ2 for 8 h, and the cell pel-
let was embedded in hydrophilic resin. Semi-thin sections stained by tolui-
dine blue show cell shrinkage and nuclear condensation (arrow heads) (B).
TEM analysis of ultra-thin section after metal stain revealed typical apopto-
tic feature. Cells were small, and contained pyknotic nuclei, electron-dense
granules and many vacuoles (D). (A and C) Control specimens without
stimulation by 15d-PGJ2. Bar=5 mm.
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Figure 6 Effects of 15d-PGJ2 on OUMS-27 cells analysed by ﬂow cytometry. The cells were incubated with or without 15d-PGJ2 (10 mgm l
71) for 4, 24 h
and then analysed by ﬂow cytometry. Cells were labelled with annexin-V-FITC and propidium iodide (PI) to distinguish apoptotic and/or necrotic cells from
normal cells. Four hours incubation with 15d-PGJ2 caused early apoptotic change (annexin-V positive, PI negative) in 53.9% of the cells. The necrotic cells
(annexin-V positive, PI positive) were also detected in 22.3%. The population of apoptotic cells increased to 67.6% at 24 h after treatment with 15d-PGJ2.
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the 15d-PGJ2-induced apoptosis in OUMS-27.
We also demonstrated that the ligands of PPARg, both pioglita-
zone and 15d-PGJ2, inhibited cell growth and induced cell death in
a dose dependent manner. The 15d-PGJ2 had more noticeable
effects on OUMS-27 cell growth than pioglitazone. Thus, it is still
unclear whether the effects of ligands on OUMS-27 cells were
strictly due to PPARg activation. The detailed analysis of the effects
of ligands on the cells which do not express PPARg should provide
important clues to understand this phenomenon. Okura et al
(2000) demonstrated that troglitazone can induce vascular smooth
muscle cell apoptosis via the tumour suppressor p53, but not by
PPARg activation. We have previously shown by functional analysis
of separated alleles in yeast (FASAY) assay that the p53-gene status
of OUMS-27 is a mutant-type (Kunisada et al, 1998). The mutant
p53 is known to inhibit the tumour-suppressor activity of wild-
type p53 protein (Levine, 1997). In this line, mutant status of
p53 might be involved in the pathway of the inhibition of
OUMS-27 cell growth by PPARg ligands. Other studies indicated
that inhibition of transcriptional activation by nuclear receptors
can be effected by competition for limited amounts of co-activators
such as cAMP response element binding protein (CREB)-binding
protein (CBP)/p300, Src-1 or TIF1 (Kamei et al, 1996; Go ¨ttlicher
et al, 1998; Sheppard et al, 1998). It may be speculated that the
difference in the recruitment of co-activators might inﬂuence the
effectiveness of each ligand.
It has been shown that PPARg has regulatory functions in the
cell cycle by altering cell growth (Motomura et al, 2000; Okura
et al, 2000; Morrison and Farmer, 1999). Recently, Motomura et
al (2000) reported that activation of PPARg by troglitazone inhib-
ited cell growth and G1 arrest through the increase of cycline
dependent kinase inhibitor p27
Kip1 in human pancreatic carcinoma
cells. They found that the effect of troglitazone on the proliferation
of cancer cells was inhibited by antisense for p27
Kip1. We have also
found by immunohistochemistry that OUMS-27 cells express
p27
Kip1 at the protein level after incubation with 15d-PGJ2
(10 mgm l
71) for 4 h, but failed to show its expression by Western
blot analysis (data not shown). Further cell cycle analysis on
p27
Kip1 is under investigation to elucidate the mechanism of
PPARg ligands-induced cell growth inhibition in OUMS-27 cells.
In conclusion, the current study showed that PPARg activators
induce apoptosis of human chondrosarcoma cells, suggesting that
PPARg activators might have potential therapeutic beneﬁt in the
treatment of chondrosarcoma. The signal transduction pathway
for the induction of apoptosis is still unclear. Whether 15d-PGJ2
can also induce tumour cell death in experimentally transplanted
chondrosarcoma models remains to be examined.
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